Literature DB >> 1125725

Hydroxyproline excretion in patients with breast cancer and response to treatment.

T J Powles, C L Leese, P K Bondy.   

Abstract

The urinary excretion of hydroxyproline, measured as the hydroxyproline: creatinine ratio, was useful in monitoring the progression of metastatic cancer of the breast. After new treatment was started changes in the hydroxyproline excretion occurred earlier than other clinically observable responses. The test could therefore be used for predicting the response to treatment and early detection of the sensitivity of the tumour to hormone therapy.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1125725      PMCID: PMC1675963          DOI: 10.1136/bmj.2.5964.164

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  7 in total

1.  ISOTOPIC STUDIES ON COLLAGEN DEGRADATION AND THE URINE EXCRETION OF HYDROXYPROLINE.

Authors:  D J PROCKOP
Journal:  J Clin Invest       Date:  1964-03       Impact factor: 14.808

2.  A specific method for the analysis of hydroxyproline in tissues and urine.

Authors:  D J PROCKOP; S UDENFRIEND
Journal:  Anal Biochem       Date:  1960-11       Impact factor: 3.365

3.  Isotopic studies on urinary hydroxyproline as evidence for rapidly catabolized forms of collagen in the young rat.

Authors:  S LINDSTEDT; D J PROCKOP
Journal:  J Biol Chem       Date:  1961-05       Impact factor: 5.157

4.  Urinary hydroxyproline excretion in early and advanced breast cancer-a sequential study.

Authors:  A Cuschieri
Journal:  Br J Surg       Date:  1973-10       Impact factor: 6.939

5.  'Early' breast cancer, bone scanning, and the urinary excretion of hydroxyproline.

Authors:  D S Sumner; M Baum; V Parsons; M H Edwards
Journal:  Br J Surg       Date:  1973-04       Impact factor: 6.939

6.  Influence of estradiol and estriol on urinary excretion of hydroxyproline in man.

Authors:  F H Katz; A Kappas
Journal:  J Lab Clin Med       Date:  1968-01

7.  The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer.

Authors:  T J Powles; S A Clark; D M Easty; G C Easty; A M Neville
Journal:  Br J Cancer       Date:  1973-10       Impact factor: 7.640

  7 in total
  9 in total

1.  Agents affecting osteolysis in patients with breast cancer.

Authors:  R C Coombes; A M Neville; J C Gazet; H T Ford; A G Nash; J W Baker; J T Powles
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Calcium metabolism in breast cancer.

Authors:  R C Coombes; T J Powles; D G Joplin
Journal:  Proc R Soc Med       Date:  1977-03

3.  Urinary hydroxyproline in the management of breast cancer.

Authors:  A Cuschieri
Journal:  World J Surg       Date:  1977-05       Impact factor: 3.352

4.  Evaluation of biochemical markers in breast cancer.

Authors:  R C Coombes; T J Powles; A M Neville
Journal:  Proc R Soc Med       Date:  1977-12

5.  Lack of hormonal changes in postmenopausal women of equal weight with and without osteoporosis, including relation to time of menopause.

Authors:  H Rico; A Charro; I Depablos; E Bordiu; E R Hernandez; D Espinos
Journal:  Clin Rheumatol       Date:  1984-09       Impact factor: 2.980

6.  Free serum hydroxyproline and total urinary hydroxyproline for the detection of skeletal metastasis.

Authors:  A B Gasser; D Depierre; B Mermillod; B Courvoisier
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

7.  Total urinary and free serum hydroxyproline in metastatic bone disease.

Authors:  A B Gasser; D Depierre; B Courvoisier
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640

8.  Relevance of hydroxyproline excretion to bone metastasis in breast cancer.

Authors:  F Gielen; J Dequeker; A Drochmans; J Wildiers; M Merlevede
Journal:  Br J Cancer       Date:  1976-09       Impact factor: 7.640

9.  Three-centre study on urinary hydroxyproline excretion in cancer of the breast.

Authors:  A Cuschieri; R Jarvie; W H Taylor; E Cant; C M Furnival; L H Blumgart
Journal:  Br J Cancer       Date:  1978-06       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.